Exploring the clinical outcomes and potential AEs associated with PD-L1 inhibitors, such as atezolizumab, durvalumab, pembrolizumab, and nivolumab, may provide valuable insights into the role of immunotherapy in improving outcomes for patients with SCLC. Here, CD274 is linked to small cell lung carcinoma.